Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379

(2020) Jan Martin Berke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

JNJ-56136379, an HBV Capsid Assembly Modulator, is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients with Chronic Infection

(2020) Fabien Zoulim et al.   GASTROENTEROLOGY

Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A–H clinical isolates and core site-directed mutants in vitro

(2020) Thierry Verbinnen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antiviral Activity and Pharmacokinetics of the HBV Capsid Assembly Modulator GLS4 in Patients with Chronic HBV Infection

(2020) Hong Zhang et al.   CLINICAL INFECTIOUS DISEASES

A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants

(2020) Sheng Feng et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection

(2019) Man Fung Yuen et al.   GASTROENTEROLOGY

FRI-180-JNJ-64530440, a novel capsid assembly modulator: single- and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers

(2019) Thomas Kakuda et al.   JOURNAL OF HEPATOLOGY

A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers

(2019) Nan Zhao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial

(2019) Man-Fung Yuen et al.   Lancet Gastroenterology & Hepatology

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

(2018) Norah A. Terrault et al.   HEPATOLOGY

RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated

(2018) E. Gane et al.   JOURNAL OF HEPATOLOGY

Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy

(2018) Meng-Lan Wang et al.   Infectious Diseases

Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients

(2018) Barbara Testoni et al.   JOURNAL OF HEPATOLOGY

Hepatitis B cure: From discovery to regulatory approval

(2017) Anna S. Lok et al.   HEPATOLOGY

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

(2017) Pietro Lampertico et al.   JOURNAL OF HEPATOLOGY

Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®)

(2014) Thierry Poynard et al.   JOURNAL OF HEPATOLOGY

Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency

(2013) Danny Ka-Ho Wong et al.   Clinical Gastroenterology and Hepatology

Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B

(2010) Patrick Marcellin et al.   LIVER INTERNATIONAL